SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on January 6, 2016. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on the dissemination of a corporate presentation.
Guidance, Outlook, and Management Commentary
- Regulation FD Disclosure (Item 7.01): The Company attached a presentation (Exhibit 99.1) dated January 2016, which is used by management in meetings and conferences to describe the Company.
- Legal Status of Information: The information contained in the presentation is explicitly not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Signatory: The report was signed by Mark L. Baum, Chief Executive Officer.
Key Facts for Investor Verification
- Verify the content of Exhibit 99.1 (Presentation dated January 2016) for specific business updates, as the 8-K itself contains no operational data.
- Note that the presentation materials are not legally filed under the Exchange Act and carry different liability standards than formal financial reports.
- Confirm the company name discrepancy: The request metadata listed "HARROW, INC.", but the filing is for Imprimis Pharmaceuticals, Inc.